Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease

Journal of Clinical Investigation

Volumn 100, Issue 8, 1997, Pages 2125-2132

  McNurlan, Margaret A ^a   Garlick, Peter J ^a   Steigbigel, Roy T ^a   DeCristofaro, Kim A ^a   Frost, Robert A ^a   Lang, Charles H ^a   Johnson, Richard W ^a   Santasier, Anita M ^a   Cabahug, Corazon J ^a   Fuhrer, Jack ^a   Gelato, Marie C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

3 methyl histidine; Insulin like growth factor I; Muscle function; Protein degradation

Indexed keywords

3 METHYLHISTIDINE; CREATININE; HUMAN GROWTH HORMONE; MUSCLE PROTEIN; PHENYLALANINE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUSCLE ATROPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SKELETAL MUSCLE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0030779626     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119747     Document Type: Article

References (57)

1. Kotler, D.P., J. Wang, and R. Pierson. 1985. Studies of body composition in patients with the acquired immunodeficiency syndrome. Am. J. Clin. Nutr. 42:1255-1265.
2. Serwadda, D., N.K. Sewankambo, J.W. Carswell, A.C. Bayley, R.S. Tedder, R.A. Weiss, A. Lwegaba, G.B. Kirya, R.G. Downing, S.A. Clayden, and A.G. Dalgleish. 1985. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet. ii:850-852.
3. Chlebowski, R.T., M.B. Grosvenor, N.H. Berhard, L.S. Morales, and L.M. Bulcavage. 1989. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am. J. Gastroenterol. 84:1288-1293.
4. Guenter, P., N. Muurahainen, G. Simons, A. Kosok, G.R. Cohan, R. Rudenstein, and J.L. Turner. 1993. Relationships among nutritional status, disease progression and survival in HIV infection. J. Acquired Immune Defic. Syndr. 6:1130-1138.
5. Anonymous. 1987. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbid. Mortal. Wkly Rep. 36:3-15.
6. Cutler, D.P., A.R. Tierney, A. Francisco, J. Wang, and R.N. Pierson, Jr. 1989. The magnitude of body cell mass depletion determines the timing of death from wasting in AIDS. Am. J. Clin. Nutr. 50:444-447.
7. Palanicek, J.P., N.M.H. Graham, Y.D. He, D.A. Hoover, J.S. Oishi, L. Kingsley, and A.J. Saah. 1995. Weight loss prior to clinical AIDS as a predictor of survival. J. Acquired Immune Defic. Syndr. 10:366-373.
8. Turner, J., N. Muurahainen, C. Terrell, C. Graeber, and C. Kotler. 1994. Nutritional status and quality of life. Int. Conf. AIDS. 2:35 (Abstr.).
9. Cohan, G.R., N. Muurahainen, P. Guenter, A. Kosok, and J.L. Turner. 1992. HIV-related hospitalizations, CD4 percent and nutritional markers. Int. Conf. Acquired Immune Defic. Syndr. 1:67 (Abstr.).
10. Süttman, U., J. Ockenga, O. Selberg, L. Hoogestraat, H. Deicher, and M.J. Müller. 1995. Incidence and prognostic value of malnutrition and wasting in HIV-infected outpatients. J. Acquired Immune Defic. Syndr. 8:239-246.
11. Ott, M., H. Fischer, H. Polat, E.B. Helm, M. Frenz, W.F. Caspary, and B. Lembcke. 1995. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J. Acquired Immune Defic. Syndr. 9:20-25.
12. Pisters, P.W., and D.B. Pearlstone. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. 1993. Crit. Rev. Clin. Lab. Sci. 30:223-272.
13. Garlick, P.J., and J. Wernerman. 1997. Protein metabolism in injury. In Scientific Foundations of Trauma. G. Cooper, H. Dudley, R. Little, and R. Maynard, editors. Butterworth/Heineman, Oxford.
14. Ott, M., B. Lembck, H. Fischer, R. Jager, H. Polat, H. Geier, M. Rech, S. Staszeswki, E.B. Helm, and W.F. Caspary. 1993. Early changes of body composition in human immunodeficiency virus-infected patients; tetrapolar body impedance analysis indicates significant malnutrition. Am. J. Clin. Nutr. 57:15-19.
15. Grunfeld, C., and K.R. Feingold. 1992. Seminars in medicine of the Beth Israel Hospital, Boston. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N. Engl. J. Med. 327:329-337.
16. Essen, P., M.A. McNurlan, T. Sonnenfeld, E. Milne, E. Vinnars, J. Wernerman, and P.J. Garlick. 1993. Muscle protein synthesis after operation: the effects of intravenous nutrition. Eur. J. Surg. 159:195-200.
17. Ward, H.C., D. Halliday, and A.J.W. Sim. 1987. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann. Surg. 206:56-61.
18. Mjaaland, M., K. Unneberg, R. Hotvedt, and A. Revhaug. 1991. Nitrogen retention caused by growth hormone in patients undergoing gastrointestinal surgery with epidural analgesia and parenteral nutrition. Eur. J. Surg. 157: 21-27.
19. Douglas, R.G., D.A. Humberstone, A. Haystead, and J.H.F. Shar. 1990. Metabolic effects of recombinant human growth hormone: isotopic studies on the postabsorptive state and during total parenteral nutrition. Br. J. Surg. 77: 785-790.
20. Voerman, H.J., R.J. Strack van Schijndel, A.B. Johan Groeneveld, H. de Boer, J.P. Nauta, and L.G. Thijs. 1995. Effects of human growth hormone in critically ill nonseptic patients: Results from a prospective, randomized, placebo-controlled trial. Crit. Care Med. 23:665-673.
21. Mulligan, K., C. Grunfeld, M.K. Hellerstein, R.A. Neese, and M. Schambelan. 1993. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77:956-962.
22. Krentz, A.J., F.T. Koster, D.M. Crist, K. Finn, L.Z. Johnson, P.J. Boyle, and D.S. Schade. 1993. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J. Acquired Immune Defic. Syndr. 6:245-251.
23. Ellis, K.J., P.D.K. Lee, J.M. Pivarnik, J.G. Bukar, and N. Gesundheit. 1996. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J. Clin. Endocrinol. Metab. 81:3033-3038.
24. Macallan, D.C., M.A. McNurlan, E. Milne, A.G. Calder, P.J. Garlick, and G.E. Griffin. 1995. Whole body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am. J. Clin. Nutr. 61:818-826.
25. 5]phenylalanine. Am. J. Physiol. 267:E102-E108.
26. 5-phenylalanine enrichment (0.002-0.09 atom percent excess), after conversion to phenylethylamine, in relation to protein turnover studies by gas chromatography/mass spectrometry. Rapid Comm. Mass Spectrom. 6:421-424.
27. Frost, R.A., J. Fuhrer, R. Steigbigel, P. Mariuz, C.H. Lang, and M.C. Gelato. 1996. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin. Endocrinol. 44:501-514.
28. Olchovsky, D., M.C. Gelato, J.F. Bruno, J. Song, and M. Berelowitz. 1991. Pituitary IGF-I content and gene expression in the streptozotocin diabetic rat: evidence for tissue specific regulation. Endocrinology. 128:923-928.
29. Wassner, S.J., J.L. Schlitzer, and J.B. Li. 1980. A rapid, sensitive method for the determination of 3-methylhistidine levels in urine and plasma using high-pressure liquid chromatography. Anal. Biochem. 104:284-289.
30. Clemmons, D.R., A. Smith-Banks, and L.E. Underwood. 1992. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J. Clin. Endocrinol. Metab. 75:234-238.
31. Fong, Y., M. Rosenbaum, K.J. Tracey, G. Raman, D.G. Hesse, D.E. Matthews, R.L. Leibel, J.M. Gertner, D.A. Rischman, and S.F. Lowry. 1989. Recombinant growth hormone enhances muscle myosin heavy-chain mRNA accumulation and amino acid accrual in humans. Proc. Natl. Acad. Sci. USA. 86: 3371-3374.
32. Lundeberg, S., M. Belfrage, J. Wernerman, A. von der Decken, S. Thunell, and E. Vinnars. 1991. Growth hormone improves muscle protein metabolism and whole body nitrogen economy in man during a hyponitrogenous diet. Metabolism. 40:315-322.
33. Hammarqvist, F., C. Strömberg, A. von der Decken, E. Vinnars, and J. Wernerman. 1992. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation. Ann. Surg. 216:184-191.
34. Wolf, R.F., D.B. Pearlstone, E. Newman, M.J. Heslin, A. Gonenne, M.E. Burt, and M.F. Brennan. 1992. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann. Surg. 216:280-312.
35. Horber, F.F., and M.W. Haymond. 1990. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J. Clin. Invest. 86:265-272.
36. Mauras, N., and B. Beaufrere. 1995. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J. Clin. Endocrinol. Metab. 80:869-874.
37. Gore, D.C., D. Honeycutt, F. Jahoor, R.R. Wolfe, and D.N. Herndon. 1991. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch. Surg. 126:38-43.
38. Aukrust, P., N.-B. Liabakk, F. Müller, E. Lien, T. Espevik, and S.S. Frøland. 1994. Serum levels of tumor necrosis-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical immunologic, and virologic parameters. J. Infect. Dis. 169:420-424.
39. Kotler, D.P., and C. Grunfeld. 1995. Pathophysiology and treatment of the AIDS wasting syndrome. AIDS Clin. Rev. 229-275.
40. Pallarés-Trujillo, J., F.J. López-Soriano, and J.M. Argilés. 1995. TNF and AIDS: two sides of the same coin? Med. Res. Rev. 15:533-546.
41. Frost, R.A., C.H. Lang, and M.C. Gelato. 1997. Transient exposure of human myoblasts to tumor necrosis factor a inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology. In press.
42. Charters, Y., and R.F. Grimble. 1989. Effect of recombinant human tumor necrosis factor a on protein synthesis in liver, skeletal muscle and skin of rats. Biochem. J. 258:493-497.
43. Flores, E.A., B.R. Bistrian, J.J. Pomposelli, C.A. Dinarello, G.L. Blackburn, and N.W. Istfan. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. J. Clin. Invest. 83:1614-1622.
44. Espat, N.J., E.M. Copeland, and L.L. Moldawer. 1994. Tumor necrosis factor and cachexia: a current perspective. Surg. Oncology. 3:255-262.
45. Fryburg, D.A., R.A. Gelfand, and E.J. Barrett. 1991. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am. J. Physiol. 260:E499-E504.
46. Fryburg, D.A., and E.J. Barrett. 1993. Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism. 42:1223-1227.
47. Fryburg, D.A. 1994. Insulin-like growth factor I exerts growth hormone-and insulin-like actions on human muscle protein metabolism. Am. J. Physiol. 267:E331-E336.
48. Rennie, M.J., K. Bennegård, E. Edén, P.W. Emery, and K. Lundholm. 1984. Urinary excretion and efflux from the leg of 3-methylhistidine before and after major surgical operation. Metabolism. 33:250-256.
49. Sjölin, J., H. Stjernström, S. Henneberg, E. Andersson, J. Mårtensson, G. Friman, and J. Larsson. 1989. Splanchnic and peripheral release of 3-methylhistidine in relation to its urinary excretion in human infection. Metabolism. 38: 23-29.
50. McNurlan, M.A., and P.J. Garlick. 1989. Influence of nutrient intake on protein turnover. Diabetes. Metab. Rev. 5:165-189.
51. Yarasheski, K.E., J.J. Azchweija, J.A. Campbell, and D.M. Bier. 1995. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am. J. Physiol. 268:E268-E276.
52. Fryburg, D.A., R.J. Louard, K.E. Gerow, R.A. Gelfand, and E.J. Barrett. 1992. Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin's antiproteolytic action in humans. Diabetes. 41:424-229.
53. Shambelan, M., K. Mulligan, C. Grunfeld, E.S. Daar, A. LaMarca, D.P. Kotler, J. Wang, S.A. Bozzette, and J.B. Breitmeyer. 1996. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann. Intern. Med. 125:873-882.
54. Macallan, D.C., C. Noble, C. Baldwin, S.A. Jebb, A.M. Prentice, A. Coward, M.B. Sawyer, T.J. McManus, and G.E. Griffin. 1995. Energy expenditure and wasting in human immunodeficiency virus infection. N. Engl. J. Med. 333:83-88.
55. Møller, J., J.O.L. Jørgensen, N. Møller, J.S. Christiansen, and J. Weeke. 1992. Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism. 41:728-731.
56. Møller, N., J.O.L. Jørgensen, P. Ovesen, O. Schmitz, K.G.M.M. Alberti, and J.S. Christiansen. 1993. Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in human. Clin. Endocrinol. 39:577-581.
57. Froesch, E.R., P.D. Zenobi, and M. Hussain. 1994. Metabolic and therapeutic effects of insulin-like growth factor I. Horm. Res. (Basel.). 42:66-71.